Cancer vaccine NY-ESO-1 - CSL/Ludwig Institute for Cancer Research

Drug Profile

Cancer vaccine NY-ESO-1 - CSL/Ludwig Institute for Cancer Research

Alternative Names: ESO-1 IMX®; ISCOMATRIX® ESO1 Therapy; Melanoma vaccine NY-ESO-1 - CSL; NY-ESO-1 ISCOMATRIX® vaccine; NY-ESO1 protein/ISCOM® adjuvant

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator CSL; Ludwig Institute for Cancer Research
  • Developer Ludwig Institute for Cancer Research
  • Class Cancer vaccines; Peptide vaccines; Peptides; Saponins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 03 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma in New Zealand, United Kingdom (IM)
  • 03 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma (Inoperable/Unresectable, Metastatic disease) in Australia (IM)
  • 20 Apr 2010 This vaccine is still in phase II trials for Malignant melanoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top